228 research outputs found
32622 Imaging technologies for presurgical margin assessment of basal cell carcinoma
Basal cell carcinoma (BCC) is the most common skin cancer worldwide. Mohs micrographic surgery is a highly used BCC treatment, involving staged resection of the tumor with complete histologic evaluation of the peripheral margins. A reduction in the number of Mohs stages would significantly improve care and could result in substantial economic benefits, estimated at $36 million USD in savings per annum. Noninvasive imaging modalities can potentially streamline the surgical management of skin cancers by refining presurgical assessments of tumor size. We assessed the current imaging techniques in dermatology and their application for tumor margin assessment of BCCs prior to Mohs micrographic surgery. These include dermoscopy, photodynamic diagnosis (PDD), high-frequency ultrasound (HFUS), optical coherence tomography (OCT), reflectance confocal microscopy (RCM), and optical polarization imaging (OPI). Each technology is limited or strengthened by its resolution, depth, speed of imaging, field of view, maneuverability, and billing. RCM, and a combination of RCM with video mosaicking technique and OCT, appear to be promising imaging techniques in pre-surgical margin assessment because of the superior resolution of RCM and the enhanced depth of imaging of OCT. OPI is also favorable for margin assessment based on its field of view and maneuverability. Further research and efficacy studies are necessary before such techniques can be implemented widely. It is imperative that general dermatologists and Mohs surgeons alike are well informed regarding the existing technologies given the increasing incidence of skin cancer and the associated rising costs
The importance of the minimum dosage necessary for UVC decontamination of N95 respirators during the COVID-19 pandemic
The World Health Organization (WHO) recently released a press report highlighting the severe shortage of personal protective equipment (PPE) that is endangering healthcare workers worldwide during the COVID-19 pandemic.(1) To meet this urgent need, healthcare institutions across the world have begun to utilize the germicidal properties of ultraviolet C (UVC) to decontaminate N95 respirators so that they can be reused.(2) It is clearly crucial that the dose of UVC delivered is sufficient to kill any viable SARS-CoV-2, the causative virus of the COVID-19 pandemic, that may be present on the respirators
Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial
BACKGROUND: Statins have beneficial effects on intrahepatic circulation and decrease portal hypertension and rifaximin modulates the gut microbiome and might prevent bacterial translocation in patients with cirrhosis. Therefore, this drug combination might be of therapeutic benefit in patients with decompensated cirrhosis. However, there is concern regarding the safety of statins in patients with decompensated cirrhosis. We assessed the safety of two different doses of simvastatin, in combination with rifaximin, in patients with decompensated cirrhosis. // METHODS: We did a double-blind, randomised, placebo-controlled, phase 2 trial in patients with decompensated cirrhosis and moderate-to-severe liver failure from nine university hospitals in six European countries (Italy, France, Holland, Germany, the UK, and Spain). Patients older than 18 years with Child-Pugh class B or C disease were eligible. We randomly assigned patients (1:1:1) to receive either simvastatin 40 mg/day plus rifaximin 1200 mg/day, simvastatin 20 mg/day plus rifaximin 1200 mg/day, or placebo of both medications for 12 weeks. Randomisation was stratified according to Child-Pugh class (B vs C) and restricted using blocks of multiples of three. The primary endpoint was development of liver or muscle toxicity, as defined by changes in liver aminotransferases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]), alkaline phosphastase, and creatine kinase. The study is registered with the European Union Clinical Trials Register, 2016-004499-23, and with ClinicalTrials.gov, NCT03150459. // FINDINGS: The study recruitment period was between July 28, 2017, and Jan 2, 2018. Follow-up finished on March 12, 2018. 50 patients were randomly assigned to simvastatin 40 mg/day plus rifaximin 1200 mg/day (n=18), simvastatin 20 mg/day plus rifaximin 1200 mg/day (n=16), or placebo of both medications (n=16). Six patients (two from each group) were excluded. Therefore, the full analysis set included 44 patients (16 in the simvastatin 40 mg/day plus rifaximin 1200 mg/day group, 14 in the simvastatin 20 mg/day plus rifaximin mg/day group, and 14 in the placebo group). After a safety analyses when the first ten patients completed treatment, treatment was stopped prematurely in the simvastatin 40 mg/day plus rifaximin group due to recommendations by the data safety monitoring board. Patients in the simvastatin 40 mg/day plus rifaximin group showed a significant increase in AST and ALT compared with the placebo group (mean differences between the groups at the end of treatment for AST 130 IU/L [95% CI 54 to 205; p=0·0009] and for ALT 61 IU/L [22 to 100; p=0·0025]. We observed no significant differences at 12 weeks in AST and ALT between the simvastatin 20 mg/day plus rifaximin and placebo group (for AST -14 IU/L [-91 to 64; p=0·728] and for ALT -8 IU/L [-49 to 33; p=0·698]). We observed no significant differences in alkaline phosphatase between the the simvastatin 40 mg/day plus rifaximin or the simvastatin 20 mg/day plus rifaximin groups compared with placebo. Patients in the simvastatin 40 mg/day plus rifaximin group showed an increase in creatine kinase at the end of treatment compared with patients in the placebo group (1009 IU/L [208 to 1809]; p=0·014). We observed no significant changes in creatine kinase in the simvastatin 20 mg/day plus rifaximin group (4·2 IU/L [-804 to 813]; p=0·992). Three (19%) patients in the simvastatin 40 mg/day group developed liver and muscle toxicity consistent with rhabdomyolysis. The number of patients who stopped treatment because of adverse events was significantly higher in the simvastatin 40 mg/day plus rifaximin group (nine [56%] of 16 patients) compared with the other two groups (two [14%] of 14 for both groups; p=0·017). There were no serious unexpected adverse reactions reported during the study. // INTERPRETATION: Treatment with simvastatin 40 mg/day plus rifaximin in patients with decompensated cirrhosis was associated with a significant increase in adverse events requiring treatment withdrawal, particularly rhabdomyolysis, compared with simvastatin 20 mg/day plus rifaximin. We recommend simvastatin 20 mg/day as the dose to be used in studies investigating the role of statins in patients with decompensated cirrhosis. //FUNDING: Horizon 20/20 European programme
<i>Gaia</i> Data Release 1. Summary of the astrometric, photometric, and survey properties
Context. At about 1000 days after the launch of Gaia we present the first Gaia data release, Gaia DR1, consisting of astrometry and photometry for over 1 billion sources brighter than magnitude 20.7.
Aims. A summary of Gaia DR1 is presented along with illustrations of the scientific quality of the data, followed by a discussion of the limitations due to the preliminary nature of this release.
Methods. The raw data collected by Gaia during the first 14 months of the mission have been processed by the Gaia Data Processing and Analysis Consortium (DPAC) and turned into an astrometric and photometric catalogue.
Results. Gaia DR1 consists of three components: a primary astrometric data set which contains the positions, parallaxes, and mean proper motions for about 2 million of the brightest stars in common with the HIPPARCOS and Tycho-2 catalogues â a realisation of the Tycho-Gaia Astrometric Solution (TGAS) â and a secondary astrometric data set containing the positions for an additional 1.1 billion sources. The second component is the photometric data set, consisting of mean G-band magnitudes for all sources. The G-band light curves and the characteristics of âŒ3000 Cepheid and RR-Lyrae stars, observed at high cadence around the south ecliptic pole, form the third component. For the primary astrometric data set the typical uncertainty is about 0.3 mas for the positions and parallaxes, and about 1 mas yrâ1 for the proper motions. A systematic component of âŒ0.3 mas should be added to the parallax uncertainties. For the subset of âŒ94 000 HIPPARCOS stars in the primary data set, the proper motions are much more precise at about 0.06 mas yrâ1. For the secondary astrometric data set, the typical uncertainty of the positions is âŒ10 mas. The median uncertainties on the mean G-band magnitudes range from the mmag level to âŒ0.03 mag over the magnitude range 5 to 20.7.
Conclusions. Gaia DR1 is an important milestone ahead of the next Gaia data release, which will feature five-parameter astrometry for all sources. Extensive validation shows that Gaia DR1 represents a major advance in the mapping of the heavens and the availability of basic stellar data that underpin observational astrophysics. Nevertheless, the very preliminary nature of this first Gaia data release does lead to a number of important limitations to the data quality which should be carefully considered before drawing conclusions from the data
The stellar halo of the Galaxy
Stellar halos may hold some of the best preserved fossils of the formation
history of galaxies. They are a natural product of the merging processes that
probably take place during the assembly of a galaxy, and hence may well be the
most ubiquitous component of galaxies, independently of their Hubble type. This
review focuses on our current understanding of the spatial structure, the
kinematics and chemistry of halo stars in the Milky Way. In recent years, we
have experienced a change in paradigm thanks to the discovery of large amounts
of substructure, especially in the outer halo. I discuss the implications of
the currently available observational constraints and fold them into several
possible formation scenarios. Unraveling the formation of the Galactic halo
will be possible in the near future through a combination of large wide field
photometric and spectroscopic surveys, and especially in the era of Gaia.Comment: 46 pages, 16 figures. References updated and some minor changes.
Full-resolution version available at
http://www.astro.rug.nl/~ahelmi/stellar-halo-review.pd
Detailed Ab Initio First-Principles Study of the Magnetic Anisotropy in a Family of Trigonal Pyramidal Iron(II) Pyrrolide Complexes
Ultracool dwarfs in Gaia DR3
Aims. In this work we use the Gaia DR3 set of ultracool dwarf candidates and
complement the Gaia spectrophotometry with additional photometry in order to
characterise its global properties. This includes the inference of the
distances, their locus in the Gaia colour-absolute magnitude diagram and the
(biased through selection) luminosity function in the faint end of the Main
Sequence. We study the overall changes in the Gaia RP spectra as a function of
spectral type. We study the UCDs in binary systems, attempt to identify
low-mass members of nearby young associations, star forming regions and
clusters, and analyse their variability properties. Results. We detect 57
young, kinematically homogeneous groups some of which are identified as well
known star forming regions, associations and clusters of different ages. We
find that the primary members of 880 binary systems with a UCD belong mainly to
the thin and thick disk components of the Milky Way. We identify 1109 variable
UCDs using the variability tables in the Gaia archive, 728 of which belong to
the star forming regions defined by HMAC. We define two groups of variable UCDs
with extreme bright or faint outliers. Conclusions. The set of sources
identified as UCDs in the Gaia archive contains a wealth of information that
will require focused follow-up studies and observations. It will help to
advance our understanding of the nature of the faint end of the Main Sequence
and the stellar/substellar transition.Comment: Accepted by Astronomy and Astrophysics. 29 pages, 20 figures plus 3
appendice
Gaia Data Release 1: Open cluster astrometry: Performance, limitations, and future prospects
Context. The first Gaia Data Release contains the Tycho-Gaia Astrometric
Solution (TGAS). This is a subset of about 2 million stars for which, besides
the position and photometry, the proper motion and parallax are calculated
using Hipparcos and Tycho-2 positions in 1991.25 as prior information. Aims. We
investigate the scientific potential and limitations of the TGAS component by
means of the astrometric data for open clusters. Methods. Mean cluster parallax
and proper motion values are derived taking into account the error correlations
within the astrometric solutions for individual stars, an estimate of the
internal velocity dispersion in the cluster, and, where relevant, the effects
of the depth of the cluster along the line of sight. Internal consistency of
the TGAS data is assessed. Results. Values given for standard uncertainties are
still inaccurate and may lead to unrealistic unit-weight standard deviations of
least squares solutions for cluster parameters. Reconstructed mean cluster
parallax and proper motion values are generally in very good agreement with
earlier Hipparcos-based determination, although the Gaia mean parallax for the
Pleiades is a significant exception. We have no current explanation for that
discrepancy. Most clusters are observed to extend to nearly 15 pc from the
cluster centre, and it will be up to future Gaia releases to establish whether
those potential cluster-member stars are still dynamically bound to the
clusters. Conclusions. The Gaia DR1 provides the means to examine open clusters
far beyond their more easily visible cores, and can provide membership
assessments based on proper motions and parallaxes. A combined HR diagram shows
the same features as observed before using the Hipparcos data, with clearly
increased luminosities for older A and F dwarfs
- âŠ